ASX ANNOUNCEMENT

Starpharma to present at Canaccord Genuity Annual Growth Conference

Melbourne, Australia; Wednesday 14 August 2013 – Starpharma Holdings Ltd (ASX:SPL; OTCQX:SPHRY) has announced that Chief Executive Officer Dr Jackie Fairley will present at the Canaccord Genuity 33rd Annual Growth Conference in Boston on August 14.

The event brings together around 200 companies from diversified industry sectors, and selected from around the world based on their high growth potential. Hundreds of sophisticated investors have registered to attend the premier North American investor conference.

As part of the conference Dr Fairley will also meet with US fund managers and investors to continue to expand awareness of Starpharma and its dendrimer platform amongst international audiences.

“We are very pleased to be invited to present as part of this important international conference which focuses on companies operating in fast growing innovation industries,” Dr Fairley said.

“Starpharma has a diverse international shareholder register, with around a third of our investors based outside of Australia, and our technologies are highly relevant to US and broader international audiences.”

“This is a great opportunity to raise awareness of Starpharma and its products with US investors.”

The presentation will provide a brief overview of the company and will include:

- Starpharma’s lead product VivaGel® for the management of bacterial vaginosis including plans for phase three clinical trials for prevention of recurrent BV;
- An overview of the attractive commercial opportunity for the VivaGel®-coated condom licensed to Ansell and Okamoto and currently under regulatory review ahead of market launch;
- The Company’s dendrimer-docetaxel formulation due to enter the clinic later this year and Starpharma’s broader drug delivery program; and
- Starpharma’s internal and partnered agrochemical program.

The presentation is attached.

ABOUT STARPHARMA

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical uses. Starpharma has three core development programs: VivaGel® portfolio, drug delivery, and agrochemicals with the Company developing a number of products internally and others via commercial partnerships.

Starpharma's lead product is VivaGel® (SPL7013 Gel), a gel-based formulation of a proprietary dendrimer. VivaGel® is under clinical development for the treatment and prevention of bacterial vaginosis (BV) and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries Inc (Tokyo Stock Exchange) to market a value-added, VivaGel®-coated condom. Ansell manufactures and sells leading condom brands worldwide, including Lifestyles®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, the world's second largest condom market.

In the wider pharmaceutical and life science fields, Starpharma has both partnered and internal programs in Drug Delivery. Drug Delivery partners include GSK, Lilly and AstraZeneca. In its internal program Starpharma has announced significant tumour-targeting results in its docetaxel (Taxotere®) program, with animal studies showing its dendrimer-enhanced version of docetaxel to have significantly superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel).

In agrochemicals Starpharma has a series of partnerships with leading industry players including Nufarm (ASX:NUF) and Makhteshim Agan as well as internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®).

FOR FURTHER INFORMATION

Media:
Buchan Consulting
Rebecca Wilson
Mob: +61 417 382 391
rwilson@buchanwe.com.au

Danny Rose
Mob: +61 407 25 00 88
drose@buchanwe.com.au

Starpharma:

Dr Jackie Fairley, Chief Executive Officer
+61 3 8532 2704

Ben Rogers, Company Secretary
ben.rogers@starpharma.com

www.starpharma.com

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

14-15 August 2013

Dr. Jackie Fairley CEO

STARPHARMA HOLDINGS LIMITED

ASX:SPL; OTCQX:SPHRY

CANACCORD GENUITY GROWTH CONFERNCE, BOSTON

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

A global leader in nanoscale polymers called dendrimers: Versatile technology & portfolio of commercial assets

VivaGel® Portfolio:

- VivaGel® for Bacterial Vaginosis (BV): Late stage Clinical Asset
- Two attractive commercial licenses for VivaGel®-coated condom: Ansell (#2 globally) and Okamoto (Japanese market leader)
- VivaGel® Microbicide Gel for HIV/HSV2/HPV prevention (STIs); Phase 2

Dendrimer Drug Delivery technology:

- Dendrimer-docetaxel demonstrated significant advantages vs. Taxotere®
- Multiple partnerships: ~ half Top 10 Pharma Companies (incl. Lilly, AstraZeneca, GSK, and multiple undisclosed)

Dendrimers in Agrochemicals:

- Internal candidates in generic agrochemicals incl. glyphosate (Roundup®)
- Multiple agrochemical partnerships incl. Nufarm (ASX:NUF), Makhteshim Agan; ~50% Top 10 Ag. companies

Corporate and financials (as of 31 July 2013)

ASX listed

Market cap: ~ A$280 million

Shares on issue: ~284 million

Compounded Annual Growth:

- SPL: 3 year 23%: 5 year 30%
- ASX 300: 3 year 3%; 5 year 0.5%

Strong institutional register

- 29% International Institutions
- 28% Australian Institutions

Major shareholders

- M&G, Acorn, Allan Gray, Dow Chemical



AUD 1: USD 0.9

Key Financial Data (Financial Year to 30 June)	FY 2012^ AUD $M
Total revenue and income	2.9
Net loss after tax	(13.7)
Cash outflow from operations	(9.8)
^Cash (30 June 2013)	33.8

Analyst Ratings			Target Price	*Price Upside
CIMB	4-Apr-13	Buy (Outperform)	$1.79	83%
NOMURA	3-Apr-13	Buy (Maintained)	$1.69	72%
CANACCORD Genuity	5-Apr-13	Buy (Maintained)	$2.00	104%
BELL POTTER	4-Apr-13	Buy (Maintained)	$1.58	61%
PhillipCapital	4-Apr-13	Buy (Maintained)	$1.90	94%
TAYLOR COLLISON	4-Apr-13	Hold (Upgraded)	$1.15	17%
* Price upside based on closing at $0.98 on 31/07/2013			Average Target Price $1.69	Average Price Upside 72%

Significant optionality: Potential for multiple and parallel revenue streams

Starpharma's Dendrimer Platform
~100 granted patents

VivaGel® Portfolio

- Condom coating
  - Ansell
  - okamoto
- Bacterial vaginosis
  - Symptomatic Relief
  - BV Prevention
- STI Prevention

Drug Delivery

- Dendrimer-Docetaxel Nanoparticle plus other off-patent drugs
- Partnered Delivery Projects
  - AstraZeneca
  - Lilly
  - GSK GlaxoSmithKline
  - ~50% Top 10 Pharma companies

Agrochemicals

- Improved Agrochemicals ie. Glyphosate
- Partnered Projects
  - Marubeni Agan
  - Nufarm
  - ~50% Top 10 Ag. companies

starpharma

VivaGel®

VivaGel®-coated condom: A compelling and differentiated product



- Condom coated with patented antiviral dendrimer (VivaGel®) shown to kill ≥ 99.99% HIV & Herpes, highly active in HPV
- Licensed to Ansell and Okamoto
  - Consumer research, product positioning, package design, manufacturing validation undertaken
- Combination product /device route: Regulatory reviews underway
- Branded condom market: $1.1B
- VivaGel® Patents to 2027

Partner	Market Position/Share	Major Brands
Okamoto Industries (listed on TSE)	• No. 1 in Japan with ~60% Japanese market (the 2nd largest condom mkt. Est. ~US$500M) • Total company revenues >US$760M	Skinless® 003® 
Ansell Limited ASX:ANN	• No. 2 globally for condom sales ~ 20% global share of branded market ~$1.1B • Condom business growing ~18%	Lifestyles® SKYN® ZERO® Manix® 

VivaGel®-coated condom: A compelling and differentiated product

- Consumer research confirms strong interest in a condom that can also inactivate STIs
- In recent qualitative research 86% of participants rated the VivaGel®-coated condom as “very interesting” with >90% saying they would buy it (research participant quotes below)

“I have never heard anything like it and I truly think it will be the no 1 leading condom, sounds too good to be true”

“I would definitely buy this product without a shadow of a doubt - it's what you want regardless of who you are with…..”

“I like the idea of a condom doing more for us than just being a barrier ……seems more reassuring to know it’s doing extra”

“I would buy this product right now if I could…..”

“I truly believe this is very interesting … it's something that is so different and unique…..It makes so much sense it's definitely one to watch well done!!!!”

“I think that this product is amazing …... This product is very special and interesting. ”

“I have rated this product a 5/5 as this is a major breakthrough in the condom market and for world health…”

Bacterial Vaginosis (BV):
An attractive commercial opportunity and unmet need

- Bacterial Vaginosis (BV) is the most common vaginal infection worldwide
- ~29% women infected in US^; up to 51% in certain demographics
- Caused by overgrowth of pathogenic bacteria* & reduction of normal flora (lactobacilli spp.)
- BV causes unpleasant discharge, irritation; PID/infertility, preterm birth, increased risk STIs e.g. HIV
- **50-60% of BV sufferers have recurrent BV (R-BV)**

BUT *current antibiotic treatments have significant shortcomings*:

  - Low cure rates; high rates of recurrence and antibiotic resistance
  - Adverse features common: GI toxicity, 2° candida, incompatibility with alcohol and condoms
  - Not suitable for long term use
- Current global market for BV treatments : ~US$300-350M
- Antibiotics not appropriate for chronic use

No products approved to prevent Recurrent BV (market est. >$1B)

^14-49 yrs; * *G. vaginalis, Bacteroides*

VivaGel® in Bacterial Vaginosis: Two product opportunities

Indication	Current Market/est.	Existing therapies	Stage of Development	Commercial Strategy
Prevention of BV Recurrence	Est. >US$1B	None approved	Phase 2 Trial results reported April 2013; **Phase 3 Planning underway**	Late stage License
BV Treatment/ Symptomatic Relief	~US $300M	Metronidazole Clindamycin (antibiotics) and various OTC	Phase 3 Completed Efficacy at 5-7 days but not at FDA endpoint(2-3wks); **Symptomatic claims being pursued**	Late stage License

Benefits of VivaGel®:

- Designed for long term use
- Not a conventional antibiotic and not systemically absorbed
- Lacks toxicities associated with antibiotics
- Selective antimicrobial effect
- Odorless and colorless water-based gel

BV Prevention of Recurrence: Phase 2 Results and Phase 3

- Double-blind exploratory Phase 2 trial in 205 US women (VivaGel® vs. placebo)
- 1% VivaGel® demonstrated reduced risk of recurrent BV (by all measures) and delayed time to first recurrence (35d vs. 5d)
- More than 80% of 1% VivaGel® users remained BV free at 16 weeks and had excellent symptomatic relief
- High levels of patient satisfaction (79% satisfied/extremely satisfied)
- VivaGel® was safe and well tolerated
- Phase 3 planning well advanced; trial due to commence late 2013 following regulatory input

R-BV Def.	R-BV Criteria	Treatment		Relative Risk Reduction (1% VivaGel vs. Placebo)
		1% SPL7013 Gel (N=65)	Placebo Gel (N=61)	
1	FDA stipulated Amsel	12%	28%	56%
2	Patient symptoms & Amsel	17%	28%	39%
3	At least 3 of the 4 Amsel criteria	22%	34%	38%
4	Investigator's determination	20%	31%	36%

" as a clinician I am very encouraged by the data for 1% VivaGel®. In this group of women almost all would have been expected to experience recurrent BV during the study. However 80% of VivaGel users remained BV free at 16 weeks.

I see this finding as highly promising – both for the management of women with this condition and for recurrent BV sufferers."

Prof. George Kinghorn, Dept. GU Medicine, Royal Hallamshire and Sheffield, UK

BV Prevention of Recurrence: Partnering and market opportunity

- Potential partners see Prevention of BV Recurrence as a “game changing” indication >$1B market opportunity
- Active engagement with ~10 top tier companies in women’s health
- Partnering discussions continuing in parallel with planning for Phase 3 trials

Prevention of Recurrence indication:

- No approved products
- Off-label use of existing products have considerable shortcomings
- High unmet need from physicians and patients with significant population of affected women
- VivaGel® demonstrated to be very safe in clinical studies >500 women
- VivaGel® is applied topically and not systemically absorbed therefore considered a better option for long term therapy



VivaGel®: Treatment and symptomatic relief of BV

Phase 3 Treatment Trials :

- Two Phase 3 double-blind, placebo controlled studies completed under IND; ~250 pp ea.
- VivaGel® (once a day for 7 days) demonstrates statistically significant Clinical Cure and effectiveness in treating symptoms of BV at the end of treatment (2-5 days: EOT)
- Primary FDA endpoint for Treatment (Cure at 2-3 weeks after cessation of treatment) not met
- VivaGel® treated women reported rapid and sustained relief from symptoms
- Excellent safety profile including very low rates of candidiasis (cf. other products)
- Patient acceptability very positive

Given the efficacy shown for VivaGel® at end of treatment and excellent symptom data:

- A number of regulatory paths, jurisdictions, and claim strategies (e.g symptomatic relief) are currently being explored with both regulators and partners
- Confounding factors including unusually high efficacy in placebo at some trial sites under discussion with FDA/Regulators as part of this investigation

starpharma

Drug Delivery

Dendrimers in drug delivery: Nanoparticles with multiple advantages

Attached Drug Molecule
(small molecule, peptide, Protein or antibody)



Drug Delivery Dendrimer

Partners including:

AstraZeneca Lilly gsk GlaxoSmithKline

Feature	Potential Benefits for Patients and/or Manufacturers
Improved Drug Efficacy	More effective treatments or lower doses
Reduced Toxicity of Actives	Reduced side-effects
Improved Drug Solubilisation	Less toxic formulations (allowing removal of toxic excipients) Less painful injection formulations
Improved Pharmacokinetics	Less frequent dosing and less severe side effects
Targeted Drug Delivery	More effective treatments; reduced side effects
Product lifecycle management	Extension of patent life: Proprietary nanoparticle formulation

Starpharma's Dendrimer-docetaxel formulation: multiple benefits

- Docetaxel (Taxotere®) is a blockbuster chemotherapeutic; 2011 sales of US$1.2B
- Docetaxel is used in major cancer types including breast, prostate and lung cancer
- Starpharma's patented Dendrimer-Docetaxel nanoparticle formulation has several significant advantages compared to original formulation of docetaxel (Taxotere®)
- Patents filed will offer coverage to 2032
- Phase 1 trial planned in 2013

Dendrimer-Docetaxel vs. Taxotere®

1. Improved water solubility allowing removal of toxic components
2. Tumour-targeting (preferential delivery to cancer tissue)
3. Extended half-life
4. Improved efficacy (breast cancer model)



TAXOTERE® (docetaxel) Injection Concentrate

Dendrimer-docetaxel benefits: efficacy and toxicity

- Docetaxel is insoluble so Taxotere® incorporates a detergent to solubilize, which is associated with significant toxicity
- Dendrimer–Docetaxel formulation is water soluble and has significantly^ better efficacy than Taxotere®
- Improved Efficacy: At 94 days:
  - 60% dendrimer-docetaxel mice - no evidence of tumour
  - 100% Taxotere® mice had tumour re-growth

Starpharma's detergent-free Dendrimer-docetaxel (solubility ↑ 2000-8000x)

Efficacy: Breast Cancer Model*



PBS 19d **Dendrimer-Docetaxel 19d**



*Mouse Xenograft (MDA- MB 231); N= 10/group ;
^ p< 0.0001

Dendrimer-docetaxel benefits: Tumour targeting and half life

- Dendrimer-Docetaxel formulation extends plasma half life by >60 fold vs. Taxotere® enabling sustained delivery of docetaxel
- Dendrimer–Docetaxel formulation provides > 40 fold greater docetaxel accumulation in tumour tissue compared to Taxotere®



^3 days post administration; n = 5 mice per group

	Plasma Half Life (hours)^
Dendrimer – Docetaxel	39
Docetaxel (Taxotere)	0.5

^n = 4 rats per group

Studies carried out in collaboration with Monash Institute of Pharmaceutical Science

Dendrimer-Docetaxel
Proposed Phase 1 Clinical Trial

- Dose escalation study in cancer patients (multiple tumour types)
- Estimated sample size: 25-30 patients
- Planning underway; expected to commence late 2013

- **Primary Objectives:**
  - Establish the maximum tolerated dose (MTD) and dose limiting toxicities (DLT)

- **Secondary Objectives:**
  - Explore preliminary anti-tumour efficacy (CT scans, bone scans, tumour markers)
  - Characterise safety and tolerability
  - Characterise pharmacokinetics
  - Define recommended dose for Phase 2

Dendrimers for drug delivery – proteins and peptide drugs



In vivo mouse model



Approach	Benefit	Status
Conjugate protein or peptide to functionalised dendrimer	**Control half life** of protein or peptide therapeutics **Improve dosing regimen** **Reduce protein metabolism**	*in vivo* using insulin for proof of concept **achieved** Co-development program with undisclosed partner

Dendrimer insulin shows prolonged suppression of blood glucose *in vivo*

Broad potential for dendrimers to improve major drugs

- Starpharma's dendrimer nanoparticle technology has broad applicability
- Analysis shows dendrimers applicable to >50% of leading pharmaceuticals
- Significant potential in oncology - Proof of concept in docetaxel, doxorubicin, paclitaxel, platinums
- Proof of concept in Insulin, other proteins, peptides

Also Suited to:

- Antibody Drug Conjugates or ADCs : Chemotherapeutic + antibody

Brand	Molecule	Innovator Company	2009 Sales ($M USD)
Taxotere	Docetaxel	Sanofi Aventis	2,140
Eloxatin	Oxaliplatin	Sanofi Aventis	1,484
Alimta	Pemetrexed	Eli Lilly	1,306
Gemzar	Gemcitabine	Eli Lilly	1,107
Doxil/caelyx	Pegylated doxorubicin	JnJ/Merck	384
Camptosar	Irinotecan	Pfizer	329
Abraxane	Albumin bound paclitaxel	Celgene	310
Vidaza	Azacitidine	Celgene	299
Taxol	Paclitaxel	BMS	292
Treanda	Bendamustine	Cephalon/Astellas	241

Nanomedicine-based oncology drug sales expected to grow to $12.7B by 2016 (CAGR 18%)

Nanotechnology in Medical Applications: The Global Market BCC 2012

Deals in Nanomedicine $700M in 2013 Amgen, Pfizer, AZ (preclinical candidates)


starpharma
Agrochemicals

Dendrimers in Agrochemicals

Dendrimers can enhance the performance of existing agrochemicals and create proprietary (patentable) formulations through:

- Extension/enhancement of effect
- Solubility enhancement
- Reduction/removal solvents – “greener” formulations
- Modification of soil penetration
- Protection of Actives/Sequestration

Partnerships with ~50% leading global Ag. Companies:

MAKHTESHIM A G A N

Nufarm

Reduced Hydrocarbon Formulations

- **Solvent-based pesticides** make up **~US$10B** of the global US$40B agrochemical market
- Dendrimers can increase water solubility **reducing the need for hydrocarbons**
- Starpharma’s aim is to develop formulations which offer:
  - **Improved environmental profile** due to a reduction in those hydrocarbon solvents
  - **Improved user and operator safety** due to the lowered solvent loading
  - Lower transport costs and improved safety due to **reduced flammability**

Source: Various AgGrow Generic Pesticides Reports

Agrochemicals: Dendrimer glyphosate formulation

- Starpharma's initial results:
  - Glyphosate (e.g. Roundup®) effectiveness measured using "brownout" (vegetation dying off)
  - Starpharma's dendrimers improved performance of glyphosate by ~160-320% compared to glyphosate alone
- Glyphosate market is US$5B globally
- Additional work also being undertaken on other key generic actives including:
  - Imidacloprid (e.g. Confidor®) globally US$1B
  - Trifluralin (e.g. Treflan™) globally US$300M



Photo depicting "brownout"

Dendrimers: Multiple products with parallel revenue streams

Product/ Application	Commercial Strategy / Partnering Status	Potential Market USD	SPL Returns
VivaGel® Bacterial Vaginosis	License at late stage	• Prevention Recurrence >$1B • Treatment/Symptomatic: ~ $350M	Royalty/milestones
VivaGel®-Coated Condom	Partnered with Ansell and Okamoto	Branded Condom Market: $1.1B	Royalties
VivaGel® Ophthalmic	Currently Internal: early partnering	Viral Conjunctivitis Market ~ $700M	Co-development/ Royalty/milestones
Drug Delivery	• Multiple Partnered (Lilly, GSK, AZ, undisclosed) • Internal: Docetaxel	• Multiple Partner Funded • Multi billion docetaxel sales	Royalty/milestones Royalty/milestones
Agrochemicals	• Multiple Partnered; Nufarm, MA & undisclosed • Internal: glyphosate, solvent removal, others	• Multiple Partner Funded (royalties/downstream returns) • Internal : ~$5 B (glyphosate), others.	Royalties Royalties

Investment proposition

Strategy: commercially exploit the dendrimer platform to generate multiple, parallel revenue streams

- A highly versatile, proprietary polymer technology platform
- Deep and diversified portfolio
- Near term commercial and clinical milestones
- An impressive and growing portfolio of commercial partnerships with leading companies
- Multiple, well advanced potential revenue streams